Should I buy or sell Amgen stock right now?

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 10 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMGN shares. View AMGN analyst ratings or view top-rated stocks .

What is Amgen's stock price target for 2024?

21 equities research analysts have issued 12 month target prices for Amgen's shares. Their AMGN share price targets range from $200.00 to $360.00. On average, they anticipate the company's stock price to reach $305.85 in the next twelve months. This suggests that the stock has a possible downside of 0.0%. View analysts price targets for AMGN or view top-rated stocks among Wall Street analysts .

How have AMGN shares performed in 2024?

Amgen's stock was trading at $288.02 at the beginning of 2024. Since then, AMGN shares have increased by 6.2% and is now trading at $305.99. View the best growth stocks for 2024 here .

Are investors shorting Amgen?

Amgen saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 9,050,000 shares, a decrease of 11.7% from the May 15th total of 10,250,000 shares. Based on an average trading volume of 2,580,000 shares, the days-to-cover ratio is currently 3.5 days. Approximately 1.7% of the shares of the stock are sold short. View Amgen's Short Interest .

When is Amgen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our AMGN earnings forecast .

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) issued its quarterly earnings results on Thursday, May, 2nd. The medical research company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.76 by $0.20. The medical research company had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a trailing twelve-month return on equity of 156.21% and a net margin of 12.74%. The company's revenue for the quarter was up 22.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.98 EPS. Read the conference call transcript .

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Wednesday, March 6th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share on Friday, June 7th. This represents a $9.00 annualized dividend and a yield of 2.94%. The ex-dividend date of this dividend is Thursday, May 16th. Read our dividend analysis for AMGN .

Is Amgen a good dividend stock?

Amgen (NASDAQ:AMGN) pays an annual dividend of $9.00 per share and currently has a dividend yield of 3.01%. The company has been increasing its dividend for 13 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 128.57%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, AMGN will have a dividend payout ratio of 43.77% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for AMGN .

What ETFs hold Amgen's stock?

ETFs with the largest weight of Amgen (NASDAQ:AMGN) stock in their portfolio include VanEck Biotech ETF (BBH) , iShares Biotechnology ETF (IBB) , Invesco Nasdaq Biotechnology ETF (IBBQ) , ProShares Ultra Nasdaq Biotechnology (BIB) , Invesco Pharmaceuticals ETF (PJP) , Horizon Kinetics Medical ETF (MEDX) , Amplify Weight Loss Drug & Treatment ETF (THNR) and Tema Cardiovascular and Metabolics ETF (HRTS) .

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of 19.000-20.200 for the period, compared to the consensus earnings per share estimate of 19.480. The company issued revenue guidance of $32.5 billion-$33.8 billion, compared to the consensus revenue estimate of $33.0 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com . Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ) , NVIDIA (NVDA) , Intel (INTC) , Cisco Systems (CSCO) , Pfizer (PFE) , AbbVie (ABBV) , Walt Disney (DIS) , AT&T (T) , Alibaba Group (BABA) and Home Depot (HD) .

Who are Amgen's major shareholders?

Amgen's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.71%), Capital International Investors (1.31%), Capital Research Global Investors (1.06%), Bank of New York Mellon Corp (1.00%), Price T Rowe Associates Inc. MD (0.58%) and Janus Henderson Group PLC (0.44%). Insiders that own company stock include Amgen Inc, Jonathan P Graham, Murdo Gordon , Nancy A Grygiel , Nancy A Grygiel , R Sanders Williams and Robert Eckert . View institutional ownership trends .

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Amgen have any subsidiaries?

The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc.. Read More

NASDAQ:AMGN

Amgen (AMGN) Stock Price, News & Analysis

→ The asset beating inflation by 4x (From Colonial Metals) (Ad)

Free AMGN Stock Alerts

$305.99

+2.71 (+0.89%)

(As of 06/18/2024 ET)

Compare

Today's Range: $302.02
▼
$306.48
50-Day Range: $262.75
▼
$319.04
52-Week Range: $218.44
▼
$329.72

Volume: 2.17 million shs
Average Volume: 2.74 million shs
Market Capitalization: $164.14 billion

P/E Ratio: 43.71
Dividend Yield: 2.94%
Price Target: $305.85

Get Amgen alerts:

Amgen MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.52 Rating Score
Upside/Downside: 0.0% Downside
$305.85 Price Target
Short Interest: Healthy
1.69% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.42
Upright™ Environmental Score
News Sentiment: 0.84
Based on 21 Articles This Week
Insider Trading: Selling Shares
$662,812 Sold Last Quarter
Proj. Earnings Growth: 5.60%
From $19.47 to $20.56 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.66 out of 5 stars

Medical Sector

60th out of 913 stocks

Biological Products, Except Diagnostic Industry

6th out of 152 stocks

2.3

Analyst's Opinion

Consensus Rating
Amgen has received a consensus rating of Moderate Buy. The company's average rating score is 2.52, and is based on 11 buy ratings, 10 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Amgen has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Read more about Amgen's stock forecast and price target.

5.0

Short Interest

Percentage of Shares Shorted
1.69% of the float of Amgen has been sold short.
Short Interest Ratio / Days to Cover
Amgen has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Amgen has recently decreased by 11.71%, indicating that investor sentiment is improving significantly.

3.3

Dividend Strength

Dividend Yield
Amgen pays a meaningful dividend of 3.01%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Amgen has been increasing its dividend for 13 years.
Dividend Coverage
The dividend payout ratio of Amgen is 128.57%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, Amgen will have a dividend payout ratio of 43.77% next year. This indicates that Amgen will be able to sustain or increase its dividend.
Read more about Amgen's dividend.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Amgen has received a 53.36% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Denosumab", "Etanercept", "Darbepoetin alfa", and "Apremilast" products. See details.
Environmental Sustainability
The Environmental Impact score for Amgen is -2.42.

2.1

News and Social Media Coverage

News Sentiment
Amgen has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 21 news articles for Amgen this week, compared to 20 articles on an average week.
Search Interest
Only 68 people have searched for AMGN on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.
MarketBeat Follows
Only 21 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is a decrease of -28% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $662,812.00 in company stock.
Percentage Held by Insiders
Only 0.69% of the stock of Amgen is held by insiders.
Percentage Held by Institutions
76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Amgen's insider trading history.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Amgen are expected to grow by 5.60% in the coming year, from $19.47 to $20.56 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amgen is 43.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.39.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amgen is 43.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 178.31.
Price to Earnings Growth Ratio
Amgen has a PEG Ratio of 2.70. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Amgen has a P/B Ratio of 26.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about Amgen's valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

[Urgent] Protect your money before November

Those who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.

Click here to watch now.

About Amgen Stock (NASDAQ:AMGN)

Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.

Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.

Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.

Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.

In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.

Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.

Written by Jeffrey Neal Johnson

AMGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AMGN Stock News Headlines

June 17 at 7:40 AM | marketbeat.com

Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines (AMGN)

Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA

June 17 at 3:27 PM | investorplace.com

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline

June 19, 2024 | Colonial Metals (Ad)

The asset beating inflation by 4x

Central Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Precious Metals Guide, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.

June 17 at 11:30 AM | seekingalpha.com

Amgen: You Haven't Seen Anything Yet

June 16 at 6:20 AM | americanbankingnews.com

Amgen Inc. (NASDAQ:AMGN) Short Interest Down 11.7% in May

June 15, 2024 | americanbankingnews.com

Royal Bank of Canada Boosts Amgen (NASDAQ:AMGN) Price Target to $332.00

June 14, 2024 | seekingalpha.com

FDA grants expanded approval for Amgen's Blincyto in ALL

June 14, 2024 | prnewswire.com

FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE

June 19, 2024 | Colonial Metals (Ad)

The asset beating inflation by 4x

June 14, 2024 | americanbankingnews.com

Critical Comparison: Amgen (NASDAQ:AMGN) versus Finch Therapeutics Group (NASDAQ:FNCH)

June 13, 2024 | investorplace.com

3 Stocks to Buy as Ozempic Surges in Popularity

June 12, 2024 | prnewswire.com

AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024

June 11, 2024 | americanbankingnews.com

Amgen Inc. Forecasted to Earn FY2025 Earnings of $19.15 Per Share (NASDAQ:AMGN)

June 10, 2024 | seekingalpha.com

Amgen Inc. (AMGN) Goldman Sachs 45th Annual Global Healthcare Conference Transcript

June 5, 2024 | prnewswire.com

AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

June 5, 2024 | reuters.com

Amgen's drug meets main goal in late-stage study for rare disease

June 5, 2024 | prnewswire.com

AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)

June 4, 2024 | seekingalpha.com

Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card

June 3, 2024 | stocknews.com

3 Biotech Stocks With Potential Breakthroughs Emerging

June 3, 2024 | prnewswire.com

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

June 3, 2024 | fool.com

The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.

May 29, 2024 | fool.com

Where Will Amgen Be in 3 Years?

May 28, 2024 | finance.yahoo.com

Nvidia, advances in cancer research, climate change under Trump: Market Domination

May 28, 2024 | finance.yahoo.com

Tapping into the GLP-1 hype? Consider these pharma stocks.

May 28, 2024 | reuters.com

US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment

May 28, 2024 | msn.com

Dow's 325-point fall led by losses for Merck, Amgen stocks

May 28, 2024 | marketwatch.com

Merck, Amgen share losses contribute to Dow's 225-point drop

See More Headlines

Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/02/2024
Ex-Dividend for 6/7 Dividend: 5/16/2024
Dividend Payable: 6/07/2024
Today: 6/19/2024
Next Earnings (Estimated): 8/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:AMGN
CUSIP: 03116210
CIK: 318154
Web: www.amgen.com
Phone: (805) 447-1000
Fax: 805-447-1010
Employees: 26,700
Year Founded: 1980

Price Target and Rating

Average Stock Price Target: $305.85
High Stock Price Target: $360.00
Low Stock Price Target: $200.00
Potential Upside/Downside: 0.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.52
Research Coverage: 21 Analysts

Profitability

EPS (Most Recent Fiscal Year): $7.00
Trailing P/E Ratio: 43.71
Forward P/E Ratio: 15.72
P/E Growth: 2.7
Net Income: $6.72 billion
Net Margins: 12.74%
Pretax Margin: 14.71%
Return on Equity: 156.21%
Return on Assets: 10.82%

Debt

Debt-to-Equity Ratio: 11.96
Current Ratio: 1.42
Quick Ratio: 0.98

Sales & Book Value

Annual Sales: $28.19 billion
Price / Sales: 5.82
Cash Flow: $27.01 per share
Price / Cash Flow: 11.33
Book Value: $11.65 per share
Price / Book: 26.27

Miscellaneous

Outstanding Shares: 536,430,000
Free Float: 532,734,000
Market Cap: $164.14 billion
Optionable: Optionable
Beta: 0.60

Social Links

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Robert A. Bradway (Age 61)
Chairman, CEO & President
Comp: $6.73M
Mr. Peter H. Griffith (Age 65)
Executive VP & CFO
Comp: $3.07M
Mr. Esteban Santos (Age 56)
Executive Vice President of Operations
Comp: $3.01M
Dr. David M. Reese M.D. (Age 61)
Executive VP & Chief Technology Officer
Comp: $3.4M
Mr. Murdo Gordon (Age 57)
Executive Vice President of Global Commercial Operations
Comp: $3.24M
Mr. Matthew C. Busch (Age 50)
Chief Accounting Officer & VP of Finance
Mr. Mike Zahigian
Senior VP & Chief Information Officer
Dr. James E. Bradner M.D. (Age 52)
Executive VP of Research and Development & Chief Scientific Officer
Justin G. Claeys
Vice President of Investor Relations
Mr. Jonathan P. Graham (Age 63)
Executive VP, General Counsel & Secretary
Comp: $2.44M

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Amgen Stock? AMGN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Amgen Inc.:

Amgen Inc. has consistently shown strong earnings growth, with a recent quarterly earnings per share of $3.96, beating analyst estimates.
The company has a high return on equity of 156.21%, indicating efficient use of shareholder funds to generate profits.
Amgen's revenue has been steadily increasing, with a 22.0% growth compared to the same quarter last year, showcasing strong business performance.
Amgen Inc. offers a healthy dividend yield of 2.82%, providing investors with a steady income stream.
Despite a high dividend payout ratio of 128.57%, the company's ability to generate strong cash flows supports its dividend payments.

Cons

Investors should be bearish about investing in Amgen Inc. for these reasons:

Amgen's stock price may be impacted by regulatory challenges in the healthcare industry, affecting investor sentiment.
The company operates in a highly competitive market, which could lead to pricing pressures on its products and impact profitability.
There is a risk associated with the company's research and development pipeline, as failures in drug development could impact future revenue streams.
Amgen's high dividend payout ratio of 128.57% raises concerns about sustainability and future dividend growth.
Investors should consider the potential impact of macroeconomic factors on Amgen's business, such as changes in healthcare policies or regulations.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, June 8, 2024. Please send any questions or comments about these Amgen pros and cons to contact@marketbeat.com.

AMGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Amgen stock right now?: 21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 10 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMGN shares.
View AMGN analyst ratings or view top-rated stocks.
What is Amgen's stock price target for 2024?: 21 equities research analysts have issued 12 month target prices for Amgen's shares. Their AMGN share price targets range from $200.00 to $360.00. On average, they anticipate the company's stock price to reach $305.85 in the next twelve months. This suggests that the stock has a possible downside of 0.0%.
View analysts price targets for AMGN or view top-rated stocks among Wall Street analysts.
How have AMGN shares performed in 2024?: Amgen's stock was trading at $288.02 at the beginning of 2024. Since then, AMGN shares have increased by 6.2% and is now trading at $305.99.
View the best growth stocks for 2024 here.
Are investors shorting Amgen?: Amgen saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 9,050,000 shares, a decrease of 11.7% from the May 15th total of 10,250,000 shares. Based on an average trading volume of 2,580,000 shares, the days-to-cover ratio is currently 3.5 days. Approximately 1.7% of the shares of the stock are sold short.
View Amgen's Short Interest.
When is Amgen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our AMGN earnings forecast.
How were Amgen's earnings last quarter?: Amgen Inc. (NASDAQ:AMGN) issued its quarterly earnings results on Thursday, May, 2nd. The medical research company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.76 by $0.20. The medical research company had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a trailing twelve-month return on equity of 156.21% and a net margin of 12.74%. The company's revenue for the quarter was up 22.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.98 EPS.
Read the conference call transcript.
How often does Amgen pay dividends? What is the dividend yield for Amgen?: Amgen announced a quarterly dividend on Wednesday, March 6th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share on Friday, June 7th. This represents a $9.00 annualized dividend and a yield of 2.94%. The ex-dividend date of this dividend is Thursday, May 16th.
Read our dividend analysis for AMGN.
Is Amgen a good dividend stock?: Amgen (NASDAQ:AMGN) pays an annual dividend of $9.00 per share and currently has a dividend yield of 3.01%. The company has been increasing its dividend for 13 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 128.57%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, AMGN will have a dividend payout ratio of 43.77% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

What ETFs hold Amgen's stock?: ETFs with the largest weight of Amgen (NASDAQ:AMGN) stock in their portfolio include VanEck Biotech ETF (BBH), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Pharmaceuticals ETF (PJP), Horizon Kinetics Medical ETF (MEDX), Amplify Weight Loss Drug & Treatment ETF (THNR) and Tema Cardiovascular and Metabolics ETF (HRTS).
What guidance has Amgen issued on next quarter's earnings?: Amgen issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of 19.000-20.200 for the period, compared to the consensus earnings per share estimate of 19.480. The company issued revenue guidance of $32.5 billion-$33.8 billion, compared to the consensus revenue estimate of $33.0 billion.
What is Robert A. Bradway's approval rating as Amgen's CEO?: 1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.
What other stocks do shareholders of Amgen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).
Who are Amgen's major shareholders?: Amgen's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.71%), Capital International Investors (1.31%), Capital Research Global Investors (1.06%), Bank of New York Mellon Corp (1.00%), Price T Rowe Associates Inc. MD (0.58%) and Janus Henderson Group PLC (0.44%). Insiders that own company stock include Amgen Inc, Jonathan P Graham, Murdo Gordon, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams and Robert Eckert.
View institutional ownership trends.
How do I buy shares of Amgen?: Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Amgen have any subsidiaries?: The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More

This page (NASDAQ:AMGN) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Amgen (AMGN) Stock Price, News & Analysis

Amgen MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Dividend Coverage

Dividend Sustainability

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions

Earnings and Valuation

Earnings Growth

Price to Earnings Ratio vs. the Market

Price to Earnings Ratio vs. Sector

Price to Earnings Growth Ratio

Price to Book Value per Share Ratio